Breaking News

Kincell Bio to Acquire Imugene’s NC Mfg. Facility

Expands capacity to provide development and manufacturing support for the immunocellular therapy market.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Imugene, Ltd. and Kincell Bio entered a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina cGMP manufacturing facility and the transfer of process and analytical development activities to Kincell.   Under the agreement Kincell will acquire Imugene’s cGMP compliant cell therapy manufacturing facility in North Carolina for a total consideration of up to $6 million in upfront and milestone payments. Also, under a manufacturing supply a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters